The Drug Enforcement Administration seeks to make medication for opioid use disorder readily and safely available to anyone in the country who needs it. As Congressionally-mandated, medical practitioners have a new role to help patients fighting to sustain recovery and prevent opioid overdoses.

The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all DEA-registered practitioners, except veterinarians, on the treatment and management of patients with opioid or other substance use disorders.

Beginning on June 27, 2023, all DEA-registered and new medical practitioners are required to attest to completion of the training when renewing or completing an initial registration. Below is information on this new requirement.

DEA Administrator Anne Milgram’s Letter

Updated DEA Registration Certificate after Removal of X-Waiver

Waiver Elimination (MAT Act) – SAMHSA

Registration Requirements

	DEA Administrator Anne Milgram's Statement on MATE Act Requirement (PDF)
	MATE Act Training Requirements Questions & Answers
	MATE Act Training Requirements (Video) (June 2023)
	As Congressionally-mandated, medical practitioners have a new role to help patients fighting to sustain recovery and prevent opioid overdoses. All medical registrants submitting a new or renewing a current registration must attest to completing an eight-hour training to treat patients overcoming opioid and other substance use disorders.
	Registration Instructions (PDF)

Requirements for training for Medication Assisted Treatment as part of the MATE Act (PDF) (March 27, 2023)

DEA Announces Important Change to Registration Requirement (PDF) (January 12, 2023)

Guidance / Questions and Answers

Updated DEA Registration Certificate after Removal of X-Waiver (PDF)

Buprenorphine (MOUD) Q&A

Registration Q&A

Please visit SAMHSA for additional information:

https://www.samhsa.gov/medications-substance-use-disorders/provider-support-services/recommendations-curricular-elements-substance-use-disorders-training

https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement

https://www.samhsa.gov/medication-assisted-treatment

For information regarding DEA’s Diversion Control Division, contact the Diversion Control Division Policy Section at ODLP@dea.gov if you seek additional assistance regarding this or any other matter.